This seems like a relevant comparable. DXCM has a $700M market cap and ECTE has a $120M valuation. DXCM uses needle based technology and ECTE has a non-invasive solution to continuous glucose monitiring. DXCM obviously has revenues and ECTE is not quite there though ECTE also has a broad based platform for drug delivery and reading other analytes. Comments anyone? Is ECTE grossly underpriced, is DXCM overpriced and can they both be long-term winners?
Well one thing is that Dexcom has a working product on the market!
Second it is the most accurate and reliable one available at this time.
Animas insulin pump has the latest version submitted to the FDA and is awaiting approval, it will have the Dexcom integrated into the pump device resulting in no need to carry two devices. Animas pumps are one of the most widely used pumps today. this gives Dexcom access to a huge market.